Gilead agrees to acquire remaining worldwide rights of Trodelvy
Gilead Sciences (NASDAQ:GILD) in agreement with Everest Medicines to assume responsibility for clinical development and commercialization for TrodelvyÂ® (sacituzumab govitecan) in Greater China and South Korea, among other Asian markets.
Per the terms, Gilead will make a $280M upfront payment to Everest.
In addition, Everest is eligible to receive up to $175M in potential additional payments upon achievement of certain regulatory and commercial milestones.

Trodelvy is currently indicated for less common triple-negative breast cancer, and the company has filed a supplemental Biologics License Application (BLA) for the treatment in the U.S.
Gilead will also have the opportunity to recruit Everest employees working directly on the Trodelvy program.
The transaction is expected to close later this year.
Gilead (GILD) added the drug as part of its $21B acquisition of Immunomedics in 2020.

Earlier, Gilead hits six-month high on potential for Trodelvy in new breast cancer indication.